Solid Tumor Treatment in China for Russian Patients: Advanced Treatment Options
Published: Aug 31, 2026
Updated: Aug 31, 2026
Published: Aug 31, 2026
Updated: Aug 31, 2026
The treatment of cancer has come to a stage of more personalised approaches, as treatment choices are based on the type of tumor, its stage, molecular features, as well as the treatment the patient has gone through previously and their general health condition. Russian patients looking for treatment abroad have found China to be an important cancer treatment destination as it provides advanced treatment for complex or hard-to-treat tumors.
China possesses capabilities in surgical oncology, precision radiotherapy, systemic therapy, immunotherapy, molecular diagnostics, and clinical research. China has been developing particle therapy and achieving results in cell and gene therapy, leading to new opportunities for specific patient groups. Furthermore, the Chinese already have extensive experience with proton and carbon-ion therapy.
For Russian patients, however, choosing treatment abroad should not simply be based on the availability of a particular technology. The most appropriate treatment depends on the tumor's biology, stage, previous treatment, molecular profile, and whether the proposed therapy has established evidence for that specific cancer.
Solid tumors are cancers that form a mass in a particular organ or tissue. They can develop in almost any part of the body and include cancers of the lung, breast, stomach, liver, pancreas, colorectal region, prostate, kidney, brain, head and neck, and many other organs.
Treatment may involve one or several modalities, including:
Solid tumors differ substantially from one another; a multidisciplinary evaluation is essential before deciding on treatment.
Find the Right Cancer Specialist in China Get your medical records reviewed by experienced oncology specialists and understand which treatment options may be suitable for your solid tumor, based on your diagnosis, stage, molecular profile, and previous treatment.
The oncology sector in China comprises sizable specialised centres, multidisciplinary cancer programmes, highly developed radiotherapy technology, molecular diagnostics, and an expanding clinical research environment.
One important advantage is the availability of advanced radiation techniques. China has developed proton and carbon-ion treatment infrastructure, with centres offering particle therapy for selected solid tumors. A review of China's particle-therapy development reported that several proton and heavy-ion facilities had already treated thousands of patients.
China is making rapid advances in developing new cancer treatments:
"In June 2026, the National Medical Products Administration of China approved satricabtagene autoleucel (also known as satri-cel), which is used to treat some patients with advanced, untreated gastric cancer who have unresectable disease and test positive for CLDN18.2. Hence, it is the first-ever CAR-T therapy approved for the treatment of solid tumors."
This, however, does not mean that all advanced cancer patients in Russia are candidates for this type of therapy. The selection of candidates for treatment depends on the tumor markers, previous treatments, health status of the patient, and established standards of qualification of the therapy.
Surgery remains a cornerstone of treatment for many localised solid tumors. Depending on the cancer, Chinese oncology centres may offer minimally invasive, laparoscopic, robotic, organ-preserving, or complex open surgery. The objective is not simply to remove the tumor but to achieve appropriate oncological margins while preserving as much normal function as possible.
Whether minimally invasive or robotic surgery is appropriate depends on the tumor's location, size, stage, anatomy, and the surgeon's assessment.
Techniques such as intensity-modulated radiotherapy, image-guided radiotherapy, stereotactic radiotherapy, and stereotactic body radiotherapy may be considered depending on the cancer. These approaches can be particularly valuable when a tumor lies close to critical organs.
Proton therapy is one of the most advanced radiation technologies available in China. Unlike conventional photon radiation, proton beams can deposit much of their energy near a planned depth, potentially reducing unnecessary radiation exposure beyond the target.
However, proton therapy is not automatically superior to conventional radiotherapy for every patient. Its potential advantage depends heavily on tumor location and anatomy. Treatment planning should therefore compare the expected dose distribution with high-quality photon IMRT before a decision is made.
Carbon-ion radiotherapy is another specialized form of particle therapy. Its physical and biological characteristics make it particularly interesting for selected deep-seated or relatively radioresistant tumors.
It may be considered in selected cases involving tumors that are difficult to treat surgically or where conventional radiation options are limited. Nevertheless, eligibility should be determined by a radiation oncology team after reviewing the patient's imaging and previous treatment.
Modern solid-tumour treatment increasingly depends on the biological characteristics of the cancer. Immunotherapy may use immune checkpoint inhibitors to help the immune system recognise and attack cancer cells. Targeted therapies, meanwhile, are designed to interfere with specific molecular pathways that drive tumor growth. Depending on the cancer, physicians may evaluate biomarkers.
China's large oncology patient population and expanding research infrastructure have supported clinical investigation of new treatments. Depending on eligibility, international patients may be evaluated for clinical trials involving:
Clinical trials should always be assessed carefully. Experimental treatment is not necessarily more effective than established therapy, and eligibility criteria can be highly specific.
A detailed medical file can significantly improve the efficiency of an international oncology consultation.
Where necessary, medical documents may need professional translation into English or Chinese.
The process generally begins with a remote medical evaluation. The patient's records are reviewed by an oncology specialist or multidisciplinary team. If treatment in China appears appropriate, the patient can then proceed with treatment planning, travel arrangements, hospital admission, diagnostic reassessment, and therapy.
A typical journey may involve:
Find specialised oncology hospitals in China offering advanced treatment options.
Trusted by 100000+ patients and leading medical experts.
China is increasingly becoming the top choice for people who go there looking for advanced treatment for solid tumors thanks to advanced cancer centers, precision radiotherapy, multi-disciplinary oncology, molecular diagnostics, and greater availability of innovative treatments.
Among the developments in treating solid tumors in China, one can name the use of proton and carbon ion radiotherapy to treat patients who pass stringent criteria for treatment. Moreover, the adoption of immunotherapy and targeted treatments for personalised cancer care sets China apart from other countries. The approval of CAR-T therapy in 2026 clearly demonstrates the rapid changes in oncology in China.
For Russian patients, the most important consideration should be individualised treatment rather than simply seeking the newest technology. A comprehensive review of pathology, imaging, molecular characteristics, previous treatments, and overall health can help determine whether treatment in China is appropriate and which therapeutic approach may offer the greatest potential benefit.
In 2026, China approved satricabtagene autoleucel (satri-cel) for a selected group of patients with advanced gastric cancer who are CLDN18.2-positive and have an incurable illness. It is crucial to realise that this approval is limited to a particular patient category and does not imply that CAR-T treatment is appropriate for other patients with advanced cancer or solid tumors.
Pathology reports, biopsy and immunohistochemistry results, molecular testing, CT, MRI, or PET-CT imaging, prior treatment records, surgical reports, radiation plans, medication lists, and current laboratory results should all be prepared by patients. Medical records may require expert translation into either Chinese or English.
Depending on the diagnosis, treatment may involve surgery, chemotherapy, radiation, proton therapy, carbon-ion therapy, immunotherapy, targeted therapy, hormonal therapy, ablation, cellular therapies, or clinical-trial treatments. A multidisciplinary oncology team determines which combination is appropriate.
Medical record review, expert or multidisciplinary consultation, treatment plan preparation, hospital selection, travel and appointment scheduling, in-person evaluation in China, treatment, and follow-up care are typical components of the route. International patient coordinators may also help with communication, accommodations, transportation, appointments, and translation.
Tanya Bose is a medical content specialist with a strong medical background. She has completed her Bachelor's and Master’s in Biotechnology from Amity University. With a deep understanding of biomedical sciences and research, she develops authoritative and patient-focused medical content covering treatments, surgical procedures, and healthcare innovations. Her writing emphasizes accuracy, clarity, and evidence-based information to help readers better understand complex medical topics. She is dedicated to improving patient awareness and supporting informed healthcare decisions by delivering trustworthy medical insights in a clear and accessible format.
Dr. Prateek Varshney is a renowned Surgical Oncologist. He has experience of more than 15+ years in surgical Oncology. He is currently practising as a consultant at Metro Mass Hospital and Cancer Institute. He was also previously associated as a consultant with Sir Ganga Ram Hospital and as a professor at Gujarat Cancer Research Institute.
Delhi, India
Istanbul, Turkey
Istanbul, Turkey
Istanbul, Turkey
Active
.jpg)
.jpg)
